Rice University's annual Veterans Business Battle is calling for submissions. Courtesy of Rice University

Rice University's Business Veterans Association has helped military veteran raise more that $3.5 million in investments over the last seven years through it's annual pitch competition. And this year, the stakes are even higher.

The Veterans Business Battle — held April 23-24 — allows veterans to pitch their early-stage business or existing company to a panel of investors, as well as engage in educational opportunities and networking. Cash prizes are awarded for first, second, and third place pitches, ranging from $5,000 to $15,000

This year the VBB has also partnered with NextSeed Securities. The registered broker dealer and FINRA member will allow vetted startups invited to present at the event to raise capital from investments by the general public.

"Last year's online-only event gave us an opportunity to think of ways to engage new investors and expand our audience. We're excited to increase opportunities for our finalists and grow our network of investors," event co-chair Matt Wilson says in a statement.

Past competitors have run the gamut, including the likes of oil and gas drone operating company Trumbull Unmanned (which was named a Top 25 Veteran-Founded Startup by Forbes) as well as skin care lines, a body armor manufacturer, ready-to-wear boots, and a health-conscious sauces company. Several have gone on to represent small businesses at the White House.

Last year, YouMeMine, Capsulomics Inc, and Feildcraft were named finalists at the virtual event. In 2019, at a in-person competition, Amor Oral, Welcome Connect and FeedMe Fitness took the stage.

Other partners for the 2021 competition include the U.S. Small Business Administration, Bunker Labs, University of St. Thomas, Houston Community College, and Warrior Rising—a nonprofit for veterans and veteran families which will be hosting education, training, and one-on-one mentorships during the event.

To apply, applicants must submit a business plan on the competition website, vetbizbattle.org, by Feb. 5, according to a release. Businesses must have an honorably discharged veteran or active duty founder and equity holder who is running the venture. Finalists will be invited to make their business pitch at Rice University.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”